Clinical and Biological Presenting Features for Patients With Hypodiploid ALL
| Variable . | Category . | Hypodiploid . | Nonhypodiploid* . | P Value† . | ||
|---|---|---|---|---|---|---|
| 45 Chromosomes (N = 87) . | 33-44 Chromosomes (N = 15) . | 24-28 Chromosomes (N = 8) . | >45 Chromosomes (N = 1,770) . | |||
| Age (yrs) | 1-9 ≥10 | 60 (69) 27 (31) | 9 (60) 6 (40) | 5 (63) 3 (38) | 1,386 (78) 384 (22) | .007; .76 |
| WBC (×109/L) | <20 20-49 | 45 (52) 17 (20) | 8 (53) 4 (27) | 4 (50) 1 (13) | 1,113 (63) 261 (15) | .07; .88 |
| ≥50 | 25 (29) | 3 (20) | 3 (38) | 396 (22) | ||
| FAB morphology | L1 L1/L2 | 61 (70) 4 (5) | 10 (67) 2 (13) | 4 (50) 1 (13) | 1,368 (78) 152 (9) | .002; .61 |
| L2/L1 L2 | 13 (15) 9 (10) | 1 (7) 2 (13) | 1 (13) 2 (25) | 103 (6) 123 (7) | ||
| Immunophenotype | B-lineage T-lineage | 52 (93) 4 (7) | 8 (80) 2 (20) | 6 (100) 0 (0) | 1,024 (84) 198 (16) | .08; .55 |
| CD10+ CD10− | 63 (9) 6 (91) | 7 (64) 4 (36) | 6 (100) 0 (0) | 1,122 (19) 266 (81) | .08; .02 | |
| NCI Risk Group‡ | Standard Poor | 42 (48) 45 (52) | 6 (40) 9 (60) | 4 (50) 4 (50) | 1,101 (62) 669 (38) | .002; .83 |
| Philadelphia chromosome | Positive Negative | 6 (7) 81 (93) | 1 (7) 14 (93) | 0 (0) 8 (100) | 37 (2) 1,733 (98) | .004; .75 |
| Liver | Normal Moderately enlarged | 42 (48) 44 (51) | 6 (40) 7 (47) | 7 (87) 1 (13) | 874 (50) 825 (47) | .89; .02 |
| Markedly enlarged | 1 (1) | 2 (13) | 0 (0) | 64 (3) | ||
| Mediastinal mass | Absent Moderately enlarged | 85 (98) 0 (0) | 14 (93) 0 (0) | 7 (87) 1 (13) | 1,603 (91) 85 (5) | .10; .007 |
| Markedly enlarged | 2 (2) | 1 (7) | 0 (0) | 2 (5) | ||
| Lymph nodes | Normal Moderately enlarged | 41 (47) 42 (48) | 11 (73) 3 (20) | 1 (13) 5 (63) | 898 (51) 753 (43) | .84; .02 |
| Markedly enlarged | 4 (5) | 1 (7) | 2 (25) | 119 (7) | ||
| Variable . | Category . | Hypodiploid . | Nonhypodiploid* . | P Value† . | ||
|---|---|---|---|---|---|---|
| 45 Chromosomes (N = 87) . | 33-44 Chromosomes (N = 15) . | 24-28 Chromosomes (N = 8) . | >45 Chromosomes (N = 1,770) . | |||
| Age (yrs) | 1-9 ≥10 | 60 (69) 27 (31) | 9 (60) 6 (40) | 5 (63) 3 (38) | 1,386 (78) 384 (22) | .007; .76 |
| WBC (×109/L) | <20 20-49 | 45 (52) 17 (20) | 8 (53) 4 (27) | 4 (50) 1 (13) | 1,113 (63) 261 (15) | .07; .88 |
| ≥50 | 25 (29) | 3 (20) | 3 (38) | 396 (22) | ||
| FAB morphology | L1 L1/L2 | 61 (70) 4 (5) | 10 (67) 2 (13) | 4 (50) 1 (13) | 1,368 (78) 152 (9) | .002; .61 |
| L2/L1 L2 | 13 (15) 9 (10) | 1 (7) 2 (13) | 1 (13) 2 (25) | 103 (6) 123 (7) | ||
| Immunophenotype | B-lineage T-lineage | 52 (93) 4 (7) | 8 (80) 2 (20) | 6 (100) 0 (0) | 1,024 (84) 198 (16) | .08; .55 |
| CD10+ CD10− | 63 (9) 6 (91) | 7 (64) 4 (36) | 6 (100) 0 (0) | 1,122 (19) 266 (81) | .08; .02 | |
| NCI Risk Group‡ | Standard Poor | 42 (48) 45 (52) | 6 (40) 9 (60) | 4 (50) 4 (50) | 1,101 (62) 669 (38) | .002; .83 |
| Philadelphia chromosome | Positive Negative | 6 (7) 81 (93) | 1 (7) 14 (93) | 0 (0) 8 (100) | 37 (2) 1,733 (98) | .004; .75 |
| Liver | Normal Moderately enlarged | 42 (48) 44 (51) | 6 (40) 7 (47) | 7 (87) 1 (13) | 874 (50) 825 (47) | .89; .02 |
| Markedly enlarged | 1 (1) | 2 (13) | 0 (0) | 64 (3) | ||
| Mediastinal mass | Absent Moderately enlarged | 85 (98) 0 (0) | 14 (93) 0 (0) | 7 (87) 1 (13) | 1,603 (91) 85 (5) | .10; .007 |
| Markedly enlarged | 2 (2) | 1 (7) | 0 (0) | 2 (5) | ||
| Lymph nodes | Normal Moderately enlarged | 41 (47) 42 (48) | 11 (73) 3 (20) | 1 (13) 5 (63) | 898 (51) 753 (43) | .84; .02 |
| Markedly enlarged | 4 (5) | 1 (7) | 2 (25) | 119 (7) | ||
Values are the number of patients with percentages in parentheses.
Nonhypodiploid included 578 normal diploid patients, 496 pseudodiploid patients, 204 low hyperdiploid (47 to 50 chromosomes) patients, and 492 high hyperdiploid (>50 chromosomes) patients.
Global χ2 test for homogeneity; the first Pvalue refers to comparison between combined hypodiploid group and nonhypodiploid group and the second P value refers to comparison among hypodiploid subgroups.
NCl standard risk = 1 to 9 years of age with WBC count less than 50,000/μL; NCl poor risk = ≥10 years of age or WBC count ≥50,000/μL.11